Dysfunction of this pathway, such as through ADCY3 loss‐of‐function mutations, has been associated with severe early onset obesity, hyperphagia, insulin resistance, and dyslipidemia [24]. This evidence concerns the gene ADCY3 and metabolic syndrome.